Saturday, May 15, 2021
 

Takeda begins regulatory submissions for dengue vaccine

 

Latest Stories

PH logs 6,784 new Covid-19 cases, recoveries drop to 2,900

THE Philippines has logged 6,784 new cases of coronavirus disease 2019 (Covid-19) in the country while the number of...

Security audit of DITO pushed amid Chinese incursions

SENATOR Risa Hontiveros prodded the National Security Council anew to conduct a security audit of DITO Telecommunity, the third...

Duterte: PH ships in West Philippine Sea ‘won’t move an inch backward’

THE Philippine ships in the West Philippine Sea will not move an inch backward, President Rodrigo Duterte said following...

Duterte invites Enrile to discuss West Philippine Sea issues in ‘Talk to the People’ program

PRESIDENT Rodrigo Duterte has invited in his next televised address former senator Juan Ponce Enrile to discuss issues concerning...

GIR balloons to 3-month high at end-April

BOND issuances by the national government and higher gold prices increased the country’s gross international reserves (GIR) to a...

Takeda Pharmaceutical Company Limited (“Takeda”) announced that the European Medicines Agency (EMA) has accepted the company’s filing packages for its dengue vaccine candidate (TAK-003) which is being investigated for the prevention of dengue due to any dengue virus serotype in individuals ages four to 60. Takeda intends to submit regulatory filings in Argentina, Brazil, Colombia, Indonesia, Malaysia, Mexico, Singapore, Sri Lanka and Thailand during 2021.

“Submission of regulatory filings for our dengue vaccine candidate, TAK-003, marks an important development for people who are living in or traveling to communities burdened by the threat of dengue,” said Derek Wallace, VP, Dengue Global Program Leader at Takeda. “Dengue outbreaks, which result in half a million hospitalizations globally each year, can overwhelm communities and governments because of the broad impact on the health care system. With limited options to prevent the disease, there is a pressing need for widely available dengue vaccines. Takeda is committed to working with regulatory authorities and recommending bodies to support evaluation of our submissions and achieve access for TAK-003.”

Takeda is participating in the EMA’s first-ever parallel assessment of a medicinal product for use in the European Union (EU), and through the EU-M4all (previously Article 58) procedure for countries outside of the EU. Along with the scientific opinion issued by the Committee for Medicinal Products for Human Use (CHMP), national regulators in countries participating in the EU-M4all procedure will conduct their own assessments to determine if national marketing authorizations for TAK-003 are granted. Takeda is also seeking approval of TAK-003 in dengue-endemic countries that are not participating in the EU-M4all procedure.


 
 

Weather

Today's Front Page

TRY OUR DIGITAL EDITION
FREE FOR 30 DAYS

ALREADY A SUBSCRIBER?